Share this entry
Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients
By: News Feed | Last updated: 27th December 2018 | In: Haematology, Oncology, Paediatric, US FDA Onc\Haem Approvals
acute lymphoblastic leukaemia, ALL, Asparlas, B-cell lineage ALL, calaspargase pegol-mknl, FDA, leukaemia, paediatric, pegaspargase, Servier
On 20 December 2018, the FDA approved the asparagine specific enzyme calaspargase pegol-mknl (Asparlas®, Servier) as a component of multi-agent chemotherapeutic regimens for the treatment of paediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukaemia (ALL).
The approval by the FDA was based on the longer interval between doses when using Asparlas® when compared to other available pegaspargase products. Asparlas® achieved and maintained nadir serum asparaginase activity above 0.1 U/mL at a dose of 2500 U/m2 intravenously every 3 weeks (q3wk). A study in 124 patients with B-cell lineage ALL investigated the pharmacokinetics when combined with multiagent chemotherapy.
Common Grade ≥3 adverse reactions in ≥10% of patients included elevated transaminase, increased bilirubin, pancreatitis, and abnormal clotting studies. Randomised data showed that the safety of calaspargase pegol-mknl q3wk was comparable to that of pegaspargase q2wk.
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.